Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176832| Title: | Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients |
| Author: | Camprubí, Daniel Almuedo Riera, Alex Martí Soler, Helena Soriano Viladomiu, Alex Hurtado, Juan Carlos Subirà, Carme Grau Pujol, Berta Krolewiecki, Alejandro J. Muñoz Gutiérrez, José |
| Keywords: | COVID-19 Farmacologia COVID-19 Pharmacology |
| Issue Date: | 11-Nov-2020 |
| Publisher: | Public Library of Science (PLoS) |
| Abstract: | Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2. |
| Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0242184 |
| It is part of: | PLoS One, 2020, vol. 15, num. 11, p. e0242184 |
| URI: | http://hdl.handle.net/2445/176832 |
| Related resource: | https://doi.org/10.1371/journal.pone.0242184 |
| ISSN: | 1932-6203 |
| Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Medicina) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 710488.pdf | 364.87 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
